Cancer Treatment-Related Ovarian Dysfunction in Women of Childbearing Potential: Management and Fertility Preservation Options.
Anna C ReynoldsLaurie J McKenziePublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
In women of childbearing potential, ovarian dysfunction resulting from cancer therapy has profound short- and long-term implications. Ovarian dysfunction can manifest as menstrual abnormalities, hot flashes, night sweats, impaired fertility, and in the long term, increased cardiovascular risk, bone mineral density loss, and cognitive deficits. The risk of ovarian dysfunction varies between drug classes, number of received lines of therapy, chemotherapy dosage, patient age, and baseline fertility status. Currently, there is no standard clinical practice to evaluate patients for their risk of developing ovarian dysfunction with systemic therapy or means to address hormonal fluctuations during treatment. This review provides a clinical guide to obtain a baseline fertility assessment and facilitate fertility preservation discussions.
Keyphrases
- bone mineral density
- oxidative stress
- polycystic ovary syndrome
- cancer therapy
- clinical practice
- postmenopausal women
- childhood cancer
- body composition
- newly diagnosed
- ejection fraction
- stem cells
- pregnancy outcomes
- squamous cell carcinoma
- radiation therapy
- type diabetes
- depressive symptoms
- intellectual disability
- prognostic factors
- autism spectrum disorder
- insulin resistance
- skeletal muscle
- sleep quality
- cervical cancer screening